share_log

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $82 Price Target

Moomoo 24/7 ·  Apr 5 05:15

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $82 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment